本公司拟将配售事项所得款项净额总额用于以下用途(i)约50%用于支持本集团的战略投资及收购;(ii)约 30%用于本集团发展全球业务及扩展海外业务;及(iii)约20%用于营运资金及一般企业用途，以支持本集 团的业务营运及增长。 根据配售代理配售的配售股份实际数目，配售事项所得款项净额(经扣除有关配售事项的配售佣金及其 他相关开支(其中包括专业费用))约为16.35亿港元。据此，每股配售股份的净发行价约为15.13港元。 智通财经APP讯，汇聚科技(01729)发布公告，配售协议所载的所有条件已获达成，配售事项已于2026年 2月20日根据配售协议的条款及条件完成。合共1.08亿股配售股份(占紧接配售事项完成前本公司现有已 发行股本约5.45%，及紧随配售事项完成后经配发及发行配售股份扩大后的本公司已发行股本约5.16%) 已成功配售予不少于六名承配人，配售价为每股15.22港元。 ...

诚如公告所披露，配售事项的所得款项净额(配售事项所得款项)将以下列形式予以动用：(a)约30%将用 作投资及并购活动;(b)约25%将用作研究及开发，包括现有管线的临床研究以及开发新管线;(c)约20%将 用作扩展新兴市场;及(d)约25%将用作一般营运资金用途。 配售事项的所得款项总额合共约为7.11亿港元。配售事项的所得款项净额，经扣除相关成本及开支、佣 金及徵费，约为6.73亿港元(按此基准，每股配售股份净价格约为30.77港元)。 MIRXES-B(02629)发布公告，董事会宣布，所有条件已达成，而交割已于2026年2月5日进行。合共 2188.8万股配售股份已成功由配售代理根据配售协议的条款及条件按配售价每股配售股份32.50港元配售 予不少于六名独立承配人。据董事作出一切合理查询后所深知、尽悉及确信，承配人连同彼等各自的最 终实益拥有人均为独立于本公司及本公司关连人士，且与本公司及本公司关连人士概无关连的第三方。 ...

Group 1 - The core point of the article is that Kexuan Power Holdings (00476.HK) has completed a placement of 20 million shares at a price of HKD 0.78 per share, with net proceeds of approximately HKD 15.4 million [1] - The placement was made to no less than six subscribers, and all conditions precedent of the placement agreement have been fulfilled [1] - The company plans to use the net proceeds for general working capital, with approximately HKD 12 million allocated for the development and expansion of its new energy business, particularly in electric commercial solutions [1][1] Group 2 - An additional HKD 3.4 million from the net proceeds will be used to supplement the company's general working capital [1]

配售价142.00港元较前一交易日收市价折让约[此处需补充前一交易日收市价数据才能计算折让比例]， 较前五个交易日平均收市价折让约[此处需补充前五个交易日平均收市价数据才能计算折让比例]。配售 股份占现有已发行股本约0.65%，完成后占扩大股本约0.65%。 重塑能源是一家能源集团公司，主营业务未详细提及。所得款项中，约3915万港元将用于通过偿还未偿 还银行贷款及租赁负债优化财务结构，约3915万港元用于一般公司用途。本次发行根据股东大会授予的 一般授权实施，已于2025年10月8日完成交割。 来源：新浪港股-好仓工作室 2025年10月8日，重塑能源（股份代号：2570）公告称，通过一般授权以配售新H股方式融资，发行 563,340股（约0.0亿股），募集约8000万港元（扣除费用后净得约7830万港元）。本次融资由中金公 司、招商证券国际担任联席整体协调人兼联席配售代理。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方 ...

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a notable increase in refinancing activities, reflecting the ambition of domestic innovative drug companies to expand globally and leverage differentiated innovation advantages [1] Group 1: Financing Activities - The total refinancing amount in the Hong Kong market reached HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, indicating a strong demand for capital to support research and development [1] - The company Xiansheng Pharmaceutical announced a placement financing plan to raise approximately HKD 1.5535 billion by issuing 121 million shares, reflecting its strategic move during a critical development phase [2][5] Group 2: Pricing and Market Response - The placement price of HKD 12.95 per share represents an approximately 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, which is within the common discount range of 5%-10% for stock issuances in the Hong Kong market [5][6] - The issuance of 121 million new shares will account for approximately 4.66% of the expanded total issued share capital, balancing the company's financing needs with shareholder interests [6] - Following the announcement, the stock price of Xiansheng Pharmaceutical experienced short-term fluctuations, but the trading volume exceeded 180 million shares, setting a new record since its listing, indicating strong market interest [7] Group 3: Company Performance and Strategy - Xiansheng Pharmaceutical has transformed into a leading innovative drug company, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, which will enhance the company's global pipeline and validate its Biopharma value [9]